The Foundation for the National Institutes of Health (FNIH) today bestowed its annual Trailblazer Prize for Clinician-Scientists to Michael Wilson, M.D., of the University of California San Francisco (UCSF).
The Foundation for the National Institutes of Health (FNIH) is honored to announce Anthony S. Fauci, M.D., as the recipient of the 2020 Charles A. Sanders, M.D., Partnership Award.
North Bethesda, MD, September 15, 2020 – The Foundation for the National Institutes of Health (FNIH) and the National Institute of Mental Health (NIMH), a part of the National Institutes of Health (NIH), announce the Accelerating Medicines Partnership® Program in Schizophrenia (AMP SCZ), the first neuropsychiatric project of the landmark Accelerating Medicines Partnership (AMP) program managed by the FNIH.
New Program Will Advance Best Practices for Innovative Approach to Combat Malaria
July 23, 2020 – Bethesda, MD – The Foundation for the National Institutes of Health (FNIH) today announced the launch of the GeneConvene Global Collaborative, an initiative to advance the safe and responsible exploration of genetic biocontrol technologies, a set of investigational public health tools with the potential to save lives, particularly those afflicted with mosquito-borne diseases such as malaria.
North Bethesda, MD, June 18, 2020 – The Foundation for the National Institutes of Health (FNIH) has named Aviv Regev, Ph.D., winner of the 2020 Lurie Prize in Biomedical Sciences for laying the groundwork for the field of single-cell genomics and spearheading leading-edge technologies that enable a sharper perspective on human cells and applying them to revolutionize understanding of biology and disease.
New initiative encourages innovative research on devastating neurological disease
Bethesda, MD, June 17, 2020 – The National Institutes of Health plans to invest $25 million over 5 years in a new program to spur innovative research on amyotrophic lateral sclerosis (ALS), a progressive and fatal neurological disease that weakens and eventually paralyzes voluntary muscles. Accelerating Leading-edge Science in ALS (ALS²) aims to answer critical questions about this disease.
North Bethesda, MD, June 11, 2020 – The Board of Directors of the Foundation for the National Institutes of Health (FNIH) on May 21, 2020, elected as its newest member Gilbert S. Omenn, M.D., Ph.D.
Health agencies, leading pharmaceutical companies to join forces to accelerate pandemic response
North Bethesda, MD, April 8, 2020 –The Foundation for the National Institutes of Health (FNIH) has established a Pandemic Response Fund to support the National Institutes of Health (NIH), led by Francis S. Collins, M.D., Ph.D., and NIH’s National Institute for Allergy and Infectious Diseases (NIAID), led by Anthony S. Fauci, M.D., in their efforts to rapidly end the threat from COVID-19.
Bethesda, MD, November 22, 2019 - The Accelerating Medicines Partnership Program (AMP) for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.